{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:17:28Z","timestamp":1793823448198,"version":"4.6.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41585-018-0034-9","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T14:44:56Z","timestamp":1528987496000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fl\u00f6rcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Derlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Panzica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Roland","family":"D\u00fcrr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut Achim","family":"Gr\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-2008","authenticated-orcid":false,"given":"Rachel H.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Falck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anno","family":"Graser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-6522","authenticated-orcid":false,"given":"Michael","family":"Staehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1464-410X.2004.04849.x","volume":"93","author":"GU Adiga","year":"2004","unstructured":"Adiga, G. U. et al. Characterization of bone metastases in patients with renal cell cancer. BJU Int. 93, 1237\u20131240 (2004).","journal-title":"BJU Int."},{"key":"34_CR2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","volume":"38","author":"SL Wood","year":"2012","unstructured":"Wood, S. L. & Brown, J. E. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat. Rev. 38, 284\u2013291 (2012).","journal-title":"Cancer Treat. Rev."},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","volume":"48","author":"E Woodward","year":"2011","unstructured":"Woodward, E. et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48, 160\u2013166 (2011).","journal-title":"Bone"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10555-007-9090-y","volume":"26","author":"K Weber","year":"2007","unstructured":"Weber, K., Doucet, M. & Kominsky, S. Renal cell carcinoma bone metastasis \u2014 elucidating the molecular targets. Cancer Metastasis Rev. 26, 691\u2013704 (2007).","journal-title":"Cancer Metastasis Rev"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-015-0122-0","volume":"34","author":"M Santoni","year":"2015","unstructured":"Santoni, M. et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J. Exp. Clin. Cancer Res. 34, 10 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"34_CR6","first-page":"379","volume":"19","author":"J Zekri","year":"2001","unstructured":"Zekri, J. et al. The skeletal metastatic complications of renal cell carcinoma. Int. J. Oncol. 19, 379\u2013382 (2001).","journal-title":"Int. J. Oncol."},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00520-014-2525-4","volume":"23","author":"DL Patrick","year":"2015","unstructured":"Patrick, D. L. et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support. Care Cancer 23, 1157\u20131168 (2015).","journal-title":"Support Care Cancer"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2003.11.017","volume":"45","author":"K Junker","year":"2004","unstructured":"Junker, K. et al. Genetic profile of bone metastases in renal cell carcinoma. Eur. Urol. 45, 320\u2013324 (2004).","journal-title":"Eur. Urol."},{"key":"34_CR9","unstructured":"Leitlinienprogramm Onkologie. S3 \u2014 Leitlinie, diagnostik, therapie und nachsorge des nierenzellkarzinom. AWMF http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-017OL-k_S3_Nierenzellkarzinom_2017-03.pdf (2017)."},{"issue":"Suppl. 3","key":"34_CR10","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl. 3), iii49\u201356 (2014).","journal-title":"Ann. Oncol."},{"key":"34_CR11","unstructured":"Mottet, N. et al. EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG Guidelines on Prostate Cancer. EAU http:\/\/uroweb.org\/guideline\/prostate-cancer (2018)."},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","volume":"15","author":"R Motzer","year":"2017","unstructured":"Motzer, R. et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 804\u2013834 (2017).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","volume":"15","author":"S Dabestani","year":"2014","unstructured":"Dabestani, S. et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 15, e549\u2013561 (2014).","journal-title":"Lancet Oncol."},{"key":"34_CR14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","volume":"23","author":"M Bianchi","year":"2012","unstructured":"Bianchi, M. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann. Oncol. 23, 973\u2013980 (2012).","journal-title":"Ann. Oncol"},{"key":"34_CR15","volume":"8","author":"D Santini","year":"2013","unstructured":"Santini, D. et al. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLOS One 8, e83026 (2013).","journal-title":"PLOS One"},{"key":"34_CR16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/1097-0142(19880701)62:1<98::AID-CNCR2820620118>3.0.CO;2-8","volume":"62","author":"J Aoki","year":"1988","unstructured":"Aoki, J. et al. Osteoclast-mediated osteolysis in bone metastasis from renal cell carcinoma. Cancer 62, 98\u2013104 (1988).","journal-title":"Cancer"},{"key":"34_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2478\/raon-2013-0034","volume":"48","author":"V Salapura","year":"2014","unstructured":"Salapura, V. et al. Osteoblastic bone metastases from renal cell carcinoma. Radiol. Oncol. 48, 243\u2013246 (2014).","journal-title":"Radiol. Oncol"},{"key":"34_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2214\/ajr.129.1.61","volume":"129","author":"GS Forbes","year":"1977","unstructured":"Forbes, G. S., McLeod, R. A. & Hattery, R. R. Radiographic manifestations of bone metastases from renal carcinoma. AJR Am. J. Roentgenol. 129, 61\u201366 (1977).","journal-title":"AJR Am. J. Roentgenol."},{"key":"34_CR19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10585-011-9379-7","volume":"28","author":"T Yuasa","year":"2011","unstructured":"Yuasa, T. et al. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin. Exp. Metastasis 28, 405\u2013411 (2011).","journal-title":"Clin. Exp. Metastasis"},{"key":"34_CR20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2006.10.060","volume":"52","author":"Y Toyoda","year":"2007","unstructured":"Toyoda, Y. et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur. Urol. 52, 163\u2013168 (2007).","journal-title":"Eur. Urol."},{"key":"34_CR21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00345-015-1707-0","volume":"34","author":"P Ivanyi","year":"2016","unstructured":"Ivanyi, P. et al. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival? World J. Urol. 34, 909\u2013915 (2016).","journal-title":"World J. Urol."},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2017.35.6_suppl.463","volume":"35","author":"F Ruatta","year":"2017","unstructured":"Ruatta, F. et al. Prognosis of renal cell carcinoma with bone metastases: experience in 300 consecutive patients [abstract]. J. Clin. Oncol. 35, 463 (2017).","journal-title":"J. Clin. Oncol."},{"key":"34_CR23","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2106\/00004623-200708000-00018","volume":"89","author":"PP Lin","year":"2007","unstructured":"Lin, P. P. et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J. Bone Joint Surg. Am. 89, 1794\u20131801 (2007).","journal-title":"J. Bone Joint Surg. Am."},{"key":"34_CR24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-11-145","volume":"11","author":"A Fottner","year":"2010","unstructured":"Fottner, A. et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet. Disord. 11, 145 (2010).","journal-title":"BMC Musculoskelet. Disord."},{"key":"34_CR25","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.juro.2010.12.037","volume":"185","author":"H Kume","year":"2011","unstructured":"Kume, H. et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J. Urol. 185, 1611\u20131614 (2011).","journal-title":"J. Urol."},{"key":"34_CR26","volume":"17","author":"SC Chen","year":"2016","unstructured":"Chen, S. C. & Kuo, P. L. Bone metastasis from renal cell carcinoma. Int. J. Mol. Sci. 17, E987 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"34_CR27","first-page":"53","volume":"45","author":"LD Rybak","year":"2001","unstructured":"Rybak, L. D. & Rosenthal, D. I. Radiological imaging for the diagnosis of bone metastases. Q. J. Nucl. Med. 45, 53\u201364 (2001).","journal-title":"Q. J. Nucl. Med"},{"key":"34_CR28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1259\/bjr\/52773262","volume":"82","author":"SA Sohaib","year":"2009","unstructured":"Sohaib, S. A. et al. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br. J. Radiol. 82, 632\u2013639 (2009).","journal-title":"Br. J. Radiol"},{"key":"34_CR29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdv289","volume":"26","author":"EL Gerety","year":"2015","unstructured":"Gerety, E. L. et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET\/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann. Oncol. 26, 2113\u20132118 (2015).","journal-title":"Ann. Oncol."},{"key":"34_CR30","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1200\/JCO.2003.04.073","volume":"21","author":"NS Majhail","year":"2003","unstructured":"Majhail, N. S. et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J. Clin. Oncol. 21, 3995\u20134000 (2003).","journal-title":"J. Clin. Oncol."},{"key":"34_CR31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1464-410X.2008.08150.x","volume":"103","author":"JW Park","year":"2009","unstructured":"Park, J. W., Jo, M. K. & Lee, H. M. Significance of 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 103, 615\u2013619 (2009).","journal-title":"BJU Int"},{"key":"34_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.12121460","volume":"267","author":"JS McDonald","year":"2013","unstructured":"McDonald, J. S. et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 267, 119\u2013128 (2013).","journal-title":"Radiology"},{"key":"34_CR33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11604-008-0277-0","volume":"26","author":"M Shinoto","year":"2008","unstructured":"Shinoto, M. et al. Percutaneous osteoplasty for hypervascular bone metastasis. Radiat. Med. 26, 603\u2013608 (2008).","journal-title":"Radiat. Med."},{"key":"34_CR34","first-page":"317","volume":"19","author":"OC Leung","year":"2013","unstructured":"Leung, O. C. et al. Percutaneous cementoplasty of osteolytic metastases induces immediate and long-lasting pain relief in oncological patients. Hong Kong Med. J. 19, 317\u2013322 (2013).","journal-title":"Hong Kong Med. J"},{"key":"34_CR35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.blo.0000149820.65137.b4","volume":"431","author":"B Fuchs","year":"2005","unstructured":"Fuchs, B., Trousdale, R. T. & Rock, M. G. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin. Orthop. Relat. Res. 431, 187\u2013192 (2005).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"34_CR36","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0022-5347(05)67016-4","volume":"164","author":"Y Kollender","year":"2000","unstructured":"Kollender, Y. et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J. Urol. 164, 1505\u20131508 (2000).","journal-title":"J. Urol."},{"key":"34_CR37","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.25836","volume":"117","author":"AL Alt","year":"2011","unstructured":"Alt, A. L. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117, 2873\u20132882 (2011).","journal-title":"Cancer"},{"key":"34_CR38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejso.2013.08.001","volume":"40","author":"N Hwang","year":"2014","unstructured":"Hwang, N. et al. Massive endoprosthetic replacement for bone metastases resulting from renal cell carcinoma: factors influencing patient survival. Eur. J. Surg. Oncol. 40, 429\u2013434 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"key":"34_CR39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3171\/2012.11.SPINE12111","volume":"18","author":"I Laufer","year":"2013","unstructured":"Laufer, I. et al. Local disease control for spinal metastases following \u201cseparation surgery\u201d and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J. Neurosurg. Spine 18, 207\u2013214 (2013).","journal-title":"J. Neurosurg. Spine"},{"key":"34_CR40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","volume":"366","author":"RA Patchell","year":"2005","unstructured":"Patchell, R. A. et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366, 643\u2013648 (2005).","journal-title":"Lancet"},{"key":"34_CR41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2016.6770","volume":"3","author":"R McDonald","year":"2017","unstructured":"McDonald, R. et al. Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC clinical trials group symptom control trial SC.23. JAMA Oncol. 3, 953\u2013959 (2017).","journal-title":"JAMA Oncol"},{"key":"34_CR42","first-page":"e589","volume":"5","author":"A Amini","year":"2015","unstructured":"Amini, A. et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract. Radiat. Oncol. 5, e589\u2013e596 (2015).","journal-title":"Radiat. Oncol."},{"key":"34_CR43","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","volume":"15","author":"G Meerleer De","year":"2014","unstructured":"De Meerleer, G. et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 15, e170\u2013e177 (2014).","journal-title":"Lancet Oncol."},{"key":"34_CR44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5489\/cuaj.2894","volume":"9","author":"SA North","year":"2015","unstructured":"North, S. A. et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can. Urol. Assoc. J. 9, 164\u2013170 (2015).","journal-title":"Can. Urol. Assoc. J"},{"key":"34_CR45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.6004\/jnccn.2015.0093","volume":"13","author":"NK Taunk","year":"2015","unstructured":"Taunk, N. K. et al. Spine radiosurgery in the management of renal cell carcinoma metastases. J. Natl Compr. Canc. Netw. 13, 801\u2013809 (2015).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"34_CR46","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","volume":"14","author":"AC Tree","year":"2013","unstructured":"Tree, A. C. et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 14, e28\u2013e37 (2013).","journal-title":"Lancet Oncol."},{"key":"34_CR47","unstructured":"Wowra, B. et al. CyberKnife radiosurgery for malignant spinal tumors: characterization of well-suited patients. 33, 2929\u20132934 (2008)."},{"key":"34_CR48","first-page":"476","volume":"37","author":"R Mazeron","year":"2011","unstructured":"Mazeron, R. et al. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat. Rev. 37, 476\u2013486 (2011).","journal-title":"Cancer Treat. Rev."},{"key":"34_CR49","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-017-0893-x","volume":"12","author":"K Wolf De","year":"2017","unstructured":"De Wolf, K. et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat. Oncol. 12, 157 (2017).","journal-title":"Radiat. Oncol."},{"key":"34_CR50","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1002\/cncr.26216","volume":"117","author":"EJ Wuthrick","year":"2011","unstructured":"Wuthrick, E. J. et al. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 117, 5548\u20135559 (2011).","journal-title":"Cancer"},{"key":"34_CR51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","volume":"77","author":"PJ Wersall","year":"2005","unstructured":"Wersall, P. J. et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77, 88\u201395 (2005).","journal-title":"Radiother. Oncol."},{"key":"34_CR52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(13)70556-4","volume":"15","author":"E Chow","year":"2014","unstructured":"Chow, E. et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 15, 164\u2013171 (2014).","journal-title":"Lancet Oncol."},{"key":"34_CR53","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/cncr.21410","volume":"104","author":"J Lee","year":"2005","unstructured":"Lee, J. et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104, 1894\u20131900 (2005).","journal-title":"Cancer"},{"key":"34_CR54","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","volume":"82","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky, M. J. et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82, 1744\u20131748 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"34_CR55","volume":"42","author":"MS Virk","year":"2017","unstructured":"Virk, M. S. et al. Frequency of symptomatic vertebral body compression fractures requiring intervention following single-fraction stereotactic radiosurgery for spinal metastases. Neurosurg. Focus 42, E8 (2017).","journal-title":"Neurosurg. Focus"},{"key":"34_CR56","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","volume":"25","author":"E Chow","year":"2007","unstructured":"Chow, E. et al. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol. 25, 1423\u20131436 (2007).","journal-title":"J. Clin. Oncol."},{"key":"34_CR57","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1200\/JCO.2008.19.3508","volume":"27","author":"PS Rose","year":"2009","unstructured":"Rose, P. S. et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J. Clin. Oncol. 27, 5075\u20135079 (2009).","journal-title":"J. Clin. Oncol."},{"key":"34_CR58","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/j.ijrobp.2012.04.034","volume":"84","author":"MV Cunha","year":"2012","unstructured":"Cunha, M. V. et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int. J. Radiat. Oncol. Biol. Phys. 84, e343\u2013e349 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"34_CR59","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2013.50.1411","volume":"31","author":"A Sahgal","year":"2013","unstructured":"Sahgal, A. et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J. Clin. Oncol. 31, 3426\u20133431 (2013).","journal-title":"J. Clin. Oncol."},{"key":"34_CR60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3171\/2014.7.SPINE13895","volume":"21","author":"I Thibault","year":"2014","unstructured":"Thibault, I. et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J. Neurosurg. Spine 21, 711\u2013718 (2014).","journal-title":"J. Neurosurg. Spine"},{"key":"34_CR61","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S1470-2045(13)70101-3","volume":"14","author":"A Sahgal","year":"2013","unstructured":"Sahgal, A. et al. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 14, e310\u2013e320 (2013).","journal-title":"Lancet Oncol."},{"key":"34_CR62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/2012.4.SPINE11902","volume":"17","author":"DE Heron","year":"2012","unstructured":"Heron, D. E. et al. Single-session and multisession CyberKnife radiosurgery for spine metastases-University of Pittsburgh and Georgetown University experience. J. Neurosurg. Spine 17, 11\u201318 (2012).","journal-title":"J. Neurosurg. Spine"},{"key":"34_CR63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/AJP.0000000000000255","volume":"32","author":"AF Mavrogenis","year":"2016","unstructured":"Mavrogenis, A. F. et al. Modern palliative treatments for metastatic bone disease: awareness of advantages, disadvantages, and guidance. Clin. J. Pain 32, 337\u2013350 (2016).","journal-title":"Clin. J. Pain"},{"key":"34_CR64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1102\/1470-7330.2008.9001","volume":"8","author":"A Gillams","year":"2008","unstructured":"Gillams, A. Tumour ablation: current role in the liver, kidney, lung and bone. Cancer Imaging 8, S1\u2013S5 (2008).","journal-title":"Cancer Imaging"},{"key":"34_CR65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00256-010-1010-5","volume":"40","author":"MD Lane","year":"2011","unstructured":"Lane, M. D. et al. Combination radiofrequency ablation and cementoplasty for palliative treatment of painful neoplastic bone metastasis: experience with 53 treated lesions in 36 patients. Skeletal Radiol. 40, 25\u201332 (2011).","journal-title":"Skeletal Radiol."},{"key":"34_CR66","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1007\/s00586-015-4057-0","volume":"25","author":"PS Pezeshki","year":"2016","unstructured":"Pezeshki, P. S. et al. Comparison of the effect of two different bone-targeted radiofrequency ablation (RFA) systems alone and in combination with percutaneous vertebroplasty (PVP) on the biomechanical stability of the metastatic spine. Eur. Spine J. 25, 3990\u20133996 (2016).","journal-title":"Eur. Spine J."},{"key":"34_CR67","first-page":"726","volume":"41","author":"Y Ma","year":"2018","unstructured":"Ma, Y. et al. Percutaneous image-guided ablation in the treatment of osseous metastases from non-small cell lung cancer. Cardiovasc. Intervent. Radiol. 41, 726\u2013733 (2018).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"34_CR68","first-page":"267","volume":"25","author":"N Tanigawa","year":"2018","unstructured":"Tanigawa, N. et al. Phase I\/II study of radiofrequency ablation for painful bone metastases: Japan Interventional Radiology in Oncology Study Group 0208. Cardiovasc. Intervent. Radiol. 25, 267\u2013266 (2018).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"34_CR69","unstructured":"Alemann, G. et al. Treatment of painful extraspinal bone metastases with percutaneous bipolar radiofrequency under local anesthesia: feasibility and efficacy in twenty-eight cases. J. Palliat. Med. 17, 947\u2013952 (2014)."},{"key":"34_CR70","first-page":"2913","volume":"15","author":"F Primavesi","year":"2018","unstructured":"Primavesi, F. et al. Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model. Oncol. Lett. 15, 2913\u20132920 (2018).","journal-title":"Oncol. Lett."},{"key":"34_CR71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-5347(17)60797-3","volume":"108","author":"RC Marcove","year":"1972","unstructured":"Marcove, R. C. et al. Cryosurgery in the treatment of solitary or multiple bone metastases from renal cell carcinoma. J. Urol. 108, 540\u2013547 (1972).","journal-title":"J. Urol."},{"key":"34_CR72","first-page":"753","volume":"10","author":"D Rohde","year":"2003","unstructured":"Rohde, D. et al. Regional thermoablation of local or metastatic renal cell carcinoma. Oncol. Rep. 10, 753\u2013757 (2003).","journal-title":"Oncol. Rep."},{"key":"34_CR73","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jvir.2012.03.002","volume":"23","author":"HJ Bang","year":"2012","unstructured":"Bang, H. J. et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J. Vasc. Interv. Radiol. 23, 770\u2013777 (2012).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"34_CR74","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2106\/JBJS.16.01182","volume":"99","author":"CS Gardner","year":"2017","unstructured":"Gardner, C. S. et al. Cryoablation of bone metastases from renal cell carcinoma for local tumor control. J. Bone Joint Surg. Am. 99, 1916\u20131926 (2017).","journal-title":"J. Bone Joint Surg. Am."},{"key":"34_CR75","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3892\/ol.2016.4108","volume":"11","author":"L Zugaro","year":"2016","unstructured":"Zugaro, L. et al. Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: a retrospective study by propensity analysis. Oncol. Lett. 11, 1948\u20131954 (2016).","journal-title":"Oncol. Lett"},{"key":"34_CR76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","volume":"136","author":"J Zo\u0142nierek","year":"2010","unstructured":"Zo\u0142nierek, J. et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J. Cancer Res. Clin. Oncol. 136, 371\u2013378 (2010).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"34_CR77","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clgc.2017.01.010","volume":"15","author":"S Kalra","year":"2017","unstructured":"Kalra, S. et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin. Genitourin. Cancer 15, 363\u2013370 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"34_CR78","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.26034","volume":"130","author":"S Maita","year":"2012","unstructured":"Maita, S. et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int. J. Cancer 130, 677\u2013684 (2012).","journal-title":"Int. J. Cancer"},{"key":"34_CR79","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917\u2013927 (2016).","journal-title":"Lancet Oncol."},{"key":"34_CR80","doi-asserted-by":"crossref","first-page":"20113","DOI":"10.18632\/oncotarget.15390","volume":"8","author":"M Fioramonti","year":"2017","unstructured":"Fioramonti, M. et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. Oncotarget 8, 20113\u201320121 (2017).","journal-title":"Oncotarget"},{"key":"34_CR81","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"34_CR82","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","volume":"96","author":"F Saad","year":"2005","unstructured":"Saad, F. & Lipton, A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 96, 964\u2013969 (2005).","journal-title":"BJU Int."},{"key":"34_CR83","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125\u20131132 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7","key":"34_CR84","doi-asserted-by":"crossref","first-page":"vii139","DOI":"10.1093\/annonc\/mds233","volume":"23","author":"CI Ripamonti","year":"2012","unstructured":"Ripamonti, C. I. et al. Management of cancer pain: ESMO clinical practice guidelines. Ann. Oncol. 23 (Suppl. 7), vii139\u2013154 (2012).","journal-title":"Ann. Oncol."},{"key":"34_CR85","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","volume":"16","author":"AJ Roelofs","year":"2010","unstructured":"Roelofs, A. J. et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des. 16, 2950\u20132960 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"34_CR86","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen, L. S. et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150\u20133157 (2003).","journal-title":"J. Clin. Oncol."},{"key":"34_CR87","doi-asserted-by":"crossref","first-page":"6397S","DOI":"10.1158\/1078-0432.CCR-040030","volume":"10","author":"A Lipton","year":"2004","unstructured":"Lipton, A. et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin. Cancer Res. 10, 6397S\u2013403S (2004).","journal-title":"Clin. Cancer Res."},{"key":"34_CR88","first-page":"6261","volume":"19","author":"UW Tunn","year":"2012","unstructured":"Tunn, U. W. et al. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can. J. Urol. 19, 6261\u20136267 (2012).","journal-title":"Can. J. Urol."},{"key":"34_CR89","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","volume":"66","author":"RR McKay","year":"2014","unstructured":"McKay, R. R. et al. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur. Urol. 66, 502\u2013509 (2014).","journal-title":"Eur. Urol."},{"key":"34_CR90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1302\/0301-620X.94B3.27999","volume":"94","author":"RN Thompson","year":"2012","unstructured":"Thompson, R. N. et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J. Bone Joint Surg. Br. 94, 385\u2013390 (2012).","journal-title":"J. Bone Joint Surg. Br."},{"key":"34_CR91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","volume":"13","author":"V Fusco","year":"2015","unstructured":"Fusco, V. et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin. Genitourin. Cancer 13, 287\u2013294 (2015).","journal-title":"Clin. Genitourin. Cancer"},{"key":"34_CR92","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry, D. et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22, 679\u2013687 (2014).","journal-title":"Support Care Cancer"},{"key":"34_CR93","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton, A. et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 48, 3082\u20133092 (2012).","journal-title":"Eur. J. Cancer"},{"key":"34_CR94","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341\u20131347 (2012).","journal-title":"Ann. Oncol"},{"key":"34_CR95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan, A. A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 30, 3\u201323 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"34_CR96","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1464-410X.2008.08124.x","volume":"103","author":"T Kijima","year":"2009","unstructured":"Kijima, T. et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 103, 620\u2013624 (2009).","journal-title":"BJU Int"},{"key":"34_CR97","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00776-012-0294-9","volume":"17","author":"N Takeda","year":"2012","unstructured":"Takeda, N. et al. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up. J. Orthop. Sci. 17, 770\u2013774 (2012).","journal-title":"J. Orthop. Sci."},{"key":"34_CR98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064615","volume":"8","author":"T Kijima","year":"2013","unstructured":"Kijima, T. et al. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLOS One 8, e64615 (2013).","journal-title":"PLOS One"},{"key":"34_CR99","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","volume":"108","author":"M Staehler","year":"2011","unstructured":"Staehler, M. et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int. 108, 673\u2013678 (2011).","journal-title":"BJU Int"},{"key":"34_CR100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2010.11.026","volume":"79","author":"S Lutz","year":"2011","unstructured":"Lutz, S. et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int. J. Radiat. Oncol. Biol. Phys. 79, 965\u2013976 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"34_CR101","first-page":"100","volume-title":"Breast Care (Basel)","author":"M Fischer","year":"2012","unstructured":"Fischer, M. & Kampen, W. U. Radionuclide therapy of bone metastases. Breast Care (Basel) 7, 100\u2013107 (2012)."},{"key":"34_CR102","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","volume":"16","author":"AN Serafini","year":"1998","unstructured":"Serafini, A. N. et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. 16, 1574\u20131581 (1998).","journal-title":"J. Clin. Oncol."},{"key":"34_CR103","first-page":"CD003347","volume":"7","author":"IFM Roque","year":"2011","unstructured":"Roque, I. F. M. et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst. Rev. 7, CD003347 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"34_CR104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0030-1253510","volume":"27","author":"RJ Owen","year":"2010","unstructured":"Owen, R. J. Embolization of musculoskeletal bone tumors. Semin. Intervent. Radiol. 27, 111\u2013123 (2010).","journal-title":"Semin. Intervent. Radiol."},{"key":"34_CR105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1080\/02841860701280725","volume":"46","author":"AR Forauer","year":"2007","unstructured":"Forauer, A. R. et al. Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncol. 46, 1012\u20131018 (2007).","journal-title":"Acta Oncol."},{"key":"34_CR106","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1007\/s11999-014-3734-3","volume":"472","author":"TJ Pazionis","year":"2014","unstructured":"Pazionis, T. J. et al. Embolization of hypervascular bone metastases reduces intraoperative blood loss: a case-control study. Clin. Orthop. Relat. Res. 472, 3179\u20133187 (2014).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"34_CR107","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00270-013-0740-x","volume":"37","author":"O Pellerin","year":"2014","unstructured":"Pellerin, O. et al. Management of painful pelvic bone metastasis of renal cell carcinoma using embolization, radio-frequency ablation, and cementoplasty: a prospective evaluation of efficacy and safety. Cardiovasc. Intervent. Radiol. 37, 730\u2013736 (2014).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"34_CR108","unstructured":"European Society for Medical Oncology. SOPs\/instructions for authors and templates for standard ESMO clinical practice guidelines (CPGs) and ESMO-MCBS scores. ESMO https:\/\/www.esmo.org\/content\/download\/77789\/1426712\/file\/ESMO-Clinical-Practice-Guidelines-Standard-Operating-Procedures.pdf (2018)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0034-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T13:32:08Z","timestamp":1720359128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-018-0034-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":108,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1038\/s41585-018-0034-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"14 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.G. has participated in advisory boards for Bristol Myer Squibb (BMS), Eisai, Ipsen, Novartis, Pfizer, and Roche, has received honoraria for compensation from BMS, Eisai, Ipsen, Novartis, Pfizer, and Roche, and has received travel grants from BMS, MSD Merck, Novartis, and Pfizer. B.E. has received honoraria and\/or travel grants from Pfizer. Uronauten receives no grants from the pharmaceutical industry. A.B. has participated in advisory boards for BMS, Ipsen, Novartis, Pfizer, and Roche\/Genentech. A.F. has received honoraria and\/or travel grants from Bayer, Ipsen, and Pfizer. R.H.G. has participated in advisory boards for Ipsen and Pfizer and has received travel grants from Ipsen and Pfizer. A.G. has received honoraria and\/or travel grants from Bayer, Novartis, and Pfizer. M.S. participated in advisory boards for AVEO, BMS, Eisai, EUSA Pharma, Exelixis, Ipsen, Novartis, Peloton, Pfizer, and Roche\/Genentech, has received travel grants from Bayer, BMS, Eisai, Ipsen, Novartis, and Pfizer, and has received research grants from AVEO, BMS, Eisai, Exelixis, Ipsen, Novartis, Pfizer, and Roche\/Genentech. The International Kidney Cancer Coalition (IKCC) receives grants from Global Offices of Ipsen\/Exelixis, Merck\/MDS, BMS, Pfizer, Novartis, and Eisai. T.G., T.D., M.P., H.R.D., K.A.G., C.v.F., and A.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}